Sequenom Performs More than 1,000 T21 Tests, Reports 23 Percent Revenue Increase for 2011 | GenomeWeb

By Julia Karow

This story was originally published Jan 13.

Sequenom has reported results for more than 1,000 MaterniT21 prenatal Down syndrome tests since it launched it last fall, a company official said last week.

The company also reported a 23 percent increase in preliminary revenue for 2011, and expects to raise additional capital, probably in the first half of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.